淋巴结阳性前列腺癌辅助放疗的患者选择:基于全国数据库的外部验证
本研究利用美国国家癌症数据库2004–2015年5498例接受根治性前列腺切除、盆腔淋巴结清扫及雄激素剥夺治疗(±辅助放疗)的pN1前列腺癌患者,验证既往基于单中心数据提出的辅助放疗获益算法。多因素Cox回归显示仅两组患者从辅助放疗中获益,其余约25%患者无显著生存获益,敏感性分析结果一致。
要点
- 仅1–2枚阳性淋巴结且Gleason 7–10分并pT3b/4或切缘阳性者,辅助放疗降低总死亡风险(HR=0.75)。
- 3–4枚阳性淋巴结者无论局部肿瘤特征如何均从辅助放疗获益(HR=0.57)。
- 其余约25%的pN1患者辅助放疗无显著生存获益,强调患者选择的重要性。
核心结论
- 既往提出的辅助放疗候选标准在全国性数据库中得到外部验证,仅特定pN1亚组可从辅助放疗中获得总生存获益。
研究设计与样本
- 基于美国国家癌症数据库2004–2015年5498例接受根治性前列腺切除、盆腔淋巴结清扫及雄激素剥夺治疗(±辅助放疗)的pN1前列腺癌患者进行回顾性队列分析。
- 按既往发表的算法将患者分为五组,采用多因素Cox回归分析总死亡风险,并进行了1:1倾向性评分匹配、排除术后3年内死亡及以术后6个月界定辅助放疗的敏感性分析。
主要发现
- 多因素Cox回归显示仅两组从辅助放疗中获益:①1–2枚阳性淋巴结、病理Gleason评分7–10分且pT3b/4或切缘阳性者(HR=0.75);②3–4枚阳性淋巴结者,不论局部肿瘤特征(HR=0.57),两者均p=0.01。
- 其余患者(占队列25%)辅助放疗无显著生存获益。
- 敏感性分析(1:1倾向性评分匹配、排除术后3年内死亡、以术后6个月界定辅助放疗)确认了上述结果。
关键数值与推荐
- 辅助放疗获益组1:1–2枚阳性淋巴结、病理Gleason评分7–10分、pT3b/4或切缘阳性(HR=0.75,p=0.01)。
- 辅助放疗获益组2:3–4枚阳性淋巴结,不论局部肿瘤特征(HR=0.57,p=0.01)。
- 其余25%的pN1患者辅助放疗无显著生存获益。
临床怎么用
- 对于pN1前列腺癌患者,应依据阳性淋巴结数量、Gleason评分、pT分期及切缘状态选择辅助放疗候选者,避免对无获益亚组过度治疗。
局限性
- 本研究为回顾性数据库分析,辅助放疗的界定依赖术后6个月的时间切点,可能存在选择偏倚;未报告其他具体局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Using institutional data, we have previously developed an algorithm to identify the optimal candidates for adjuvant radiotherapy (aRT) among men with pN1 prostate cancer (PCa) at radical prostatectomy (RP). This study aimed to test the external validity of our previous findings using a nationwide database while focusing on overall mortality as an endpoint. To this end, we identified 5498 pN1 PCa patients who were treated with RP, pelvic lymph node dissection, and androgen deprivation therapy with or without aRT, within the National Cancer Database, between 2004 and 2015. Patients were divided into five groups based on our previously published algorithm. Similar to our previous report, multivariable Cox regression analysis showed that only two of these groups benefit from aRT: (1) those with one to two positive nodes, pathological Gleason score 7-10, and pT3b/4 disease or positive surgical margins (hazard ratio [HR]=0.75); and (2) those with three to four positive nodes, regardless of local tumor characteristics (HR=0.57, both p=0.01). In the remaining patients (25% of the cohort), aRT had no significant survival benefit. Results were confirmed on sensitivity analyses using 1:1 propensity score-matched cohorts, excluding men who died within 3 yr of surgery and using cut-off of 6 mo post-surgery to identify receipt of aRT. Our findings corroborate the validity of our previously published criteria and highlight the importance of patient selection in pN1 PCa patients who are considered for aRT.
引用
- Abdollah F, Dalela D, Sood A, et al. Impact of Adjuvant Radiotherapy in Node-positive Prostate Cancer Patients: The Importance of Patient Selection. Eur Urol. 2018. PMID: 29720348. doi:10.1016/j.eururo.2018.04.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。